Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving. Delays in molecular testing for ...
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer Among 556 patients with mNSCLC, 98.8% received ...
When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.